Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK New Product Launches In 2004 Will Include Vesicare, Avandaryl

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline expects that Vesicare and Avandaryl will be approved before the end of the year, the company said Sept. 14 at the Bear Stearns health care conference in New York

You may also be interested in...



Takeda Files Actos/Metformin Combination Actoplus Met For Type 2 Diabetes

NDA submission of pioglitazone/metformin combo marks beginning of Takeda’s expansion in the U.S. diabetes market; the firm has insulin resistance-improving agents in Phase II and Phase III.

Takeda Files Actos/Metformin Combination Actoplus Met For Type 2 Diabetes

NDA submission of pioglitazone/metformin combo marks beginning of Takeda’s expansion in the U.S. diabetes market; the firm has insulin resistance-improving agents in Phase II and Phase III.

GSK Sweetens Early-Stage Diabetes Pipeline With HGS’ Albugon

The preclinical peptide hormone will likely be developed for Type-2 diabetes. Human Genome Sciences believes potential advantage with Albugon is prolonged half-life.

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel